April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
Acadia becomes the latest to fall foul of the US FDA's apparently increasingly strict stance.
Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
Neurocrine Biosciences' latest collaboration, with Takeda, gives it three more high-risk bets in neuroscience.
Newron’s failure in Rett syndrome leaves the late-stage pipeline to GW Pharma, Acadia and Anavex.
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.